Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,076 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state.
Teranishi-Ikawa Y, Soeda T, Koga H, Yamaguchi K, Kato K, Esaki K, Asanuma K, Funaki M, Ichiki M, Ikuta Y, Ito S, Joyashiki E, Komatsu SI, Muto A, Nishimura K, Okuda M, Sanada H, Sato M, Shibahara N, Wakabayashi T, Yamaguchi K, Matsusaki A, Sampei Z, Shiraiwa H, Konishi H, Kawabe Y, Hattori K, Kitazawa T, Igawa T. Teranishi-Ikawa Y, et al. Among authors: koga h. J Thromb Haemost. 2024 Feb;22(2):430-440. doi: 10.1016/j.jtha.2023.09.034. Epub 2023 Nov 6. J Thromb Haemost. 2024. PMID: 37940048 Free article.
Efficient production of bispecific antibody by FAST-IgTM and its application to NXT007 for the treatment of hemophilia A.
Koga H, Yamano T, Betancur J, Nagatomo S, Ikeda Y, Yamaguchi K, Nabuchi Y, Sato K, Teranishi-Ikawa Y, Sato M, Hirayama H, Hayasaka A, Torizawa T, Haraya K, Sampei Z, Shiraiwa H, Kitazawa T, Igawa T, Kuramochi T. Koga H, et al. MAbs. 2023 Jan-Dec;15(1):2222441. doi: 10.1080/19420862.2023.2222441. MAbs. 2023. PMID: 37339067 Free PMC article.
Monte Carlo Thompson sampling-guided design for antibody engineering.
Kakuzaki T, Koga H, Takizawa S, Metsugi S, Shiraiwa H, Sampei Z, Yoshida K, Tsunoda H, Teramoto R. Kakuzaki T, et al. Among authors: koga h. MAbs. 2023 Jan-Dec;15(1):2244214. doi: 10.1080/19420862.2023.2244214. MAbs. 2023. PMID: 37605371 Free PMC article.
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Żotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R; EMERALD-1 Investigators. Sangro B, et al. Lancet. 2025 Jan 8:S0140-6736(24)02551-0. doi: 10.1016/S0140-6736(24)02551-0. Online ahead of print. Lancet. 2025. PMID: 39798579
Reply to the Letter Regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study".
Kudo M, Tsuchiya K, Yamashita T, Koga H, Nakagawa Y, Ikeda M. Kudo M, et al. Among authors: koga h. Liver Cancer. 2024 May 6;13(6):671-673. doi: 10.1159/000539205. eCollection 2024 Dec. Liver Cancer. 2024. PMID: 39687035 Free PMC article. No abstract available.
2,076 results